Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet. 2008;16(6):666–72.

Article  CAS  PubMed  Google Scholar 

Maenner MJ, et al. FMR1 CGG expansions: prevalence and sex ratios. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(5):466–73.

Article  PubMed  Google Scholar 

Tassone F, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seltzer MM, et al. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):589–97.

Article  PubMed  Google Scholar 

Hipp HS, et al. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). Menopause. 2016;23(9):993–9.

Article  PubMed  PubMed Central  Google Scholar 

Johansen Taber K, et al. Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines. Mol Genet Genomic Med. 2019;7(12):e1024.

Article  PubMed  PubMed Central  Google Scholar 

Allen EG, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod. 2007;22(8):2142–52.

Article  CAS  PubMed  Google Scholar 

Hoyos LR, Thakur M. Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency. J Assist Reprod Genet. 2017;34(3):315–23.

Article  PubMed  Google Scholar 

Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011;29(4):299–307.

Article  PubMed  Google Scholar 

Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97(3):189–94.

Article  CAS  PubMed  Google Scholar 

Wittenberger MD, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007;87(3):456–65.

Article  CAS  PubMed  Google Scholar 

Allen EG, et al. Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size. Genet Med. 2021;23(9):1648–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murray A, et al. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet. 2000;8(4):247–52.

Article  CAS  PubMed  Google Scholar 

Sullivan AK, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005;20(2):402–12.

Article  CAS  PubMed  Google Scholar 

ACOG. Committee opinion no. 691: carrier screening for genetic conditions. Obstet Gynecol. 2017;129(3):e41–55.

Article  Google Scholar 

Finucane B, et al. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. J Genet Couns. 2012;21(6):752–60.

Article  PubMed  Google Scholar 

Groff AA, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril. 2005;83(6):1734–41.

Article  PubMed  Google Scholar 

Espinel W, et al. Improving health education for women who carry an FMR1 premutation. J Genet Couns. 2016;25(2):228–38.

Article  PubMed  Google Scholar 

Man L, et al. Fragile X-associated diminished ovarian reserve and primary ovarian insufficiency from molecular mechanisms to clinical manifestations. Front Mol Neurosci. 2017;10:290.

Article  PubMed  PubMed Central  Google Scholar 

Smolich L, Charen K, Sherman SL. Health knowledge of women with a fragile X premutation: improving understanding with targeted educational material. J Genet Couns. 2020;29(6):983–91.

Article  PubMed  PubMed Central  Google Scholar 

Coffey SM, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A(8):1009–16.

Article  PubMed  PubMed Central  Google Scholar 

Wheeler AC, et al. Health and reproductive experiences of women with an FMR1 premutation with and without fragile X premature ovarian insufficiency. Front Genet. 2014;5:300.

Article  PubMed  PubMed Central  Google Scholar 

Kenna HA, et al. High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(8):872–8.

Article  PubMed  PubMed Central  Google Scholar 

Hagerman RJ, et al. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry. 2018;9:564.

Article  PubMed  PubMed Central  Google Scholar 

Allen EG, et al. Clustering of comorbid conditions among women who carry an FMR1 premutation. Genet Med. 2020;22(4):758–66.

Allen EG, et al. Predictors of comorbid conditions in women who carry an FMR1 premutation. Front Psychiatry. 2021;12:715922.

Article  PubMed  PubMed Central  Google Scholar 

Abbeduto L, et al. Psychological well-being and coping in mothers of youths with autism, Down syndrome, or fragile X syndrome. Am J Ment Retard. 2004;109(3):237–54.

Article  PubMed  Google Scholar 

Anido A, et al. Women’s attitudes toward testing for fragile X carrier status: a qualitative analysis. J Genet Couns. 2005;14(4):295–306.

Article  PubMed  Google Scholar 

Wheeler A, et al. Correlates of maternal behaviours in mothers of children with fragile X syndrome. J Intellect Disabil Res. 2007;51(Pt. 6):447–62.

Article  PubMed  Google Scholar 

Hunter JE, Rohr JK, Sherman SL. Co-occurring diagnoses among FMR1 premutation allele carriers. Clin Genet. 2010;77(4):374–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Archibald AD, et al. “It gives them more options”: preferences for preconception genetic carrier screening for fragile X syndrome in primary healthcare. J Community Genet. 2016;7(2):159–71.

Article  PubMed  PubMed Central  Google Scholar 

Singer D, et al. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric. 2011;14(4):428–37.

Article  CAS  PubMed  Google Scholar 

Bailey DB Jr, et al. Maternal consequences of the detection of fragile X carriers in newborn screening. Pediatrics. 2015;136(2):e433–40.

Article  PubMed  PubMed Central  Google Scholar 

Armeni E, et al. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101561.

Article  CAS  PubMed  Google Scholar 

North American Menopause S. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257–71.